Matt Kane is the Chief Executive Officer and Director of Tune Therapeutics.
A veteran biotech leader with deep experience in advanced genetic medicines, Matt was previously the co-founder and CEO of Precision BioSciences – a company focused on developing gene and cell therapies using a novel gene editing platform.
As CEO, he led a team that raised over $400M in equity and debt financing, including an IPO in 2019, formed partnerships with leading biopharmaceutical companies valued at over $4.7B, and advanced four unique genetic medicines into human clinical trials. Matt has nearly twenty years of experience in the life sciences industry and was formerly with Suros Surgical Systems, later acquired by Hologic.
He received his B.S. and M.S. from the Rose-Hulman Institute of Technology, and an MBA from Duke University.